Once-daily tavapadon offers a new Parkinson’s treatment option, with symptom benefits supported by trials and important ...

Juvmo, the brand name for tavapadon, became the 43rd entry on the FDA’s 2026 novel drug approvals list on September 25, 2026.

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced ...

The FDA has approved tavapadon, branded Juvmo, a once-daily D1 dopamine receptor agonist for Parkinson's disease developed ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...

The US FDA has approved tavapadon (Juvmo), an oral selective D1/D5 dopamine agonist, for the treatment of adults with ...

On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the ...

Please provide your email address to receive an email when new articles are posted on . Juvmo is the first FDA-approved treatment for Parkinson’s disease to selectively target D1/D5 receptors.

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III ...

Please provide your email address to receive an email when new articles are posted on . Dopamine agonists target D2/D3 receptors, possibly increasing adverse events. Tavapadon targets D1/D5 receptors, ...

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with ...